PARAMETRIC PORTFOLIO ASSOCIATES LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 166 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.

Quarter-by-quarter ownership
PARAMETRIC PORTFOLIO ASSOCIATES LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q1 2022$11,682,000
-1.0%
292,933
-0.2%
0.01%0.0%
Q4 2021$11,804,000
+3.9%
293,558
+5.1%
0.01%0.0%
Q3 2021$11,363,000
-9.2%
279,325
+1.4%
0.01%
-14.3%
Q2 2021$12,514,000
-8.6%
275,573
-16.1%
0.01%
-12.5%
Q1 2021$13,692,000
+12.5%
328,421
+15.3%
0.01%0.0%
Q4 2020$12,170,000
+62.1%
284,954
-0.3%
0.01%
+60.0%
Q3 2020$7,509,000
+4.2%
285,716
+6.3%
0.01%
-16.7%
Q2 2020$7,208,000
+99.9%
268,873
+34.2%
0.01%
+100.0%
Q1 2020$3,605,000
-20.4%
200,412
-21.6%
0.00%0.0%
Q4 2019$4,531,000
+26.8%
255,533
+10.9%
0.00%0.0%
Q3 2019$3,574,000
+47.4%
230,406
+63.3%
0.00%
+50.0%
Q2 2019$2,425,000
+60.4%
141,131
+50.2%
0.00%
+100.0%
Q1 2019$1,512,000
+26.3%
93,940
+14.9%
0.00%0.0%
Q4 2018$1,197,000
+75.5%
81,793
+117.8%
0.00%0.0%
Q3 2018$682,000
-26.8%
37,552
-32.0%
0.00%0.0%
Q2 2018$932,000
-33.9%
55,234
-23.2%
0.00%0.0%
Q1 2018$1,409,000
-34.5%
71,900
-32.3%
0.00%
-50.0%
Q4 2017$2,151,000
+36.0%
106,148
+16.5%
0.00%0.0%
Q3 2017$1,582,000
+124.7%
91,092
+65.8%
0.00%
+100.0%
Q2 2017$704,000
+2.9%
54,934
+4.1%
0.00%0.0%
Q1 2017$684,000
+80.0%
52,784
+37.2%
0.00%0.0%
Q4 2016$380,000
-12.2%
38,476
+7.3%
0.00%0.0%
Q3 2016$433,000
+48.8%
35,861
+6.3%
0.00%
Q2 2016$291,000
-2.3%
33,732
+7.1%
0.00%
Q1 2016$298,000
-28.0%
31,482
+31.8%
0.00%
-100.0%
Q4 2015$414,000
+22.1%
23,882
-5.5%
0.00%0.0%
Q3 2015$339,000
-43.5%
25,262
-4.9%
0.00%0.0%
Q2 2015$600,000
+52.7%
26,557
-3.5%
0.00%0.0%
Q1 2015$393,000
+65.8%
27,515
+12.1%
0.00%
Q4 2014$237,000
+4.9%
24,536
-1.3%
0.00%
Q3 2014$226,000
-6.2%
24,848
+2.0%
0.00%
-100.0%
Q2 2014$241,000
-24.2%
24,349
-2.6%
0.00%0.0%
Q1 2014$318,000
-11.4%
25,008
+4.5%
0.00%0.0%
Q4 2013$359,000
+33.0%
23,933
-2.2%
0.00%0.0%
Q3 2013$270,000
+50.8%
24,462
+8.6%
0.00%0.0%
Q2 2013$179,00022,5210.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2016
NameSharesValueWeighting ↓
TRAN CAPITAL MANAGEMENT, L.P. 1,506,473$61,283,0005.13%
First Light Asset Management, LLC 1,477,496$60,105,0003.96%
SNYDER CAPITAL MANAGEMENT L P 3,427,476$139,430,0003.69%
DOHENY ASSET MANAGEMENT /CA 80,400$3,271,0002.34%
Redwood Investments, LLC 619,766$25,212,0002.11%
HighMark Wealth Management LLC 53,341$2,170,0001.60%
SILVERARC CAPITAL MANAGEMENT, LLC 60,170$2,448,0001.38%
Third Security, LLC 168,604$6,859,0001.33%
Taylor Wealth Management Partners 87,654$3,566,0001.27%
Penn Capital Management Company, LLC 290,394$11,813,0001.19%
View complete list of HALOZYME THERAPEUTICS INC shareholders